Sign in

    Hunter Diamond • Diamond Equity Research LLC

    Hunter Diamond is Chief Executive Officer and Senior Equity Analyst at Diamond Equity Research LLC, specializing in micro-capitalization and small capitalization companies across various sectors. He has provided research coverage for firms such as Genius Group Limited, delivering in-depth fundamental analysis focused on emerging growth companies with a track record of enhancing investor visibility. With credentials including the CFA designation, Hunter began his investment research career prior to founding Diamond Equity Research and has consistently led initiatives to expand coverage of under-followed equities. He holds professional licensing as a CFA Charterholder, and his leadership has positioned Diamond Equity Research as a notable provider of institutional-quality research reports.

    Hunter Diamond's questions to Bioharvest Sciences Inc (BHST) leadership

    Hunter Diamond's questions to Bioharvest Sciences Inc (BHST) leadership • Q2 2025

    Question

    Hunter Diamond of Diamond Equity Research LLC asked about the timeline for the CDMO division to begin contributing more meaningfully to revenue. He also inquired about the composition of the CDMO pipeline, specifically the breakdown between early-stage and later-stage assets.

    Answer

    CEO Ilan Sobel projected that meaningful revenue contributions from the CDMO division will begin in early 2026 as current projects advance and new ones enter the pipeline. He emphasized the high value of current projects, including a multi-billion dollar fragrance opportunity and the Tate and Lyle partnership. Sobel also explained that the new 'Discovery Phase' service is designed to accelerate the intake of new high-value projects into stage one, thereby strengthening the future revenue stream.

    Ask Fintool Equity Research AI

    Hunter Diamond's questions to Bioharvest Sciences Inc (BHST) leadership • Q2 2025

    Question

    Asked about the timeline for the CDMO business to ramp up and contribute more meaningfully to revenue, and requested details on the breakdown of contracts between different phases and where the company sees the most opportunity.

    Answer

    The CEO stated that meaningful revenue contributions from the CDMO business are expected to start in early 2026 as current projects advance through phases and new projects are signed. The current pipeline is significant, including a pharma partner already moved to Phase 2 for an approved drug, and multi-billion dollar opportunities with Tate & Lyle and a fragrance company. The new 'discovery' service is helping to convert more leads into Stage 1 projects.

    Ask Fintool Equity Research AI

    Hunter Diamond's questions to Prophase Labs Inc (PRPH) leadership

    Hunter Diamond's questions to Prophase Labs Inc (PRPH) leadership • Q3 2024

    Question

    The analyst asked about the strategy and progress regarding potential partnerships for the BE-Smart Esophageal Cancer Test, including the types of companies ProPhase is in discussions with.

    Answer

    The company is actively exploring partnerships with large, multi-billion-dollar cancer diagnostic testing companies as a path to commercialization. This strategy is seen as a way to leverage an established infrastructure, accelerate valuation, and reduce risk. The executive mentioned that these companies are keen to enter the esophageal cancer space and that ProPhase holds key IP. While discussions are ongoing and somewhat preliminary, they could accelerate quickly. A potential deal could involve upfront payments, milestones, and royalties.

    Ask Fintool Equity Research AI